Tag Archive for: Sofinnova Partners

Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startups

Delivers high-performing AI infrastructure through NVIDIA DGX Cloud Lepton to portfolio companies, creating a powerful competitive advantage in $100B+ life sciences market BioCorteX, Bioptimus, Cure51, and Latent Labs among first cohort of startups to gain GPU capacity credits, helping position Europe at forefront of AI-driven drug discovery revolution PARIS, France – June, 11, 2025 – […]

Sofinnova Partners raises €1.2 billion to fuel the next wave of life sciences innovation

Leading European venture capital firm exceeds €4 billion in assets under management, doubling its AUM in the last five years PARIS, France – March 4, 2025 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences based in Paris, London, and Milan, today announced it had raised €1.2 billion across its platform […]

Weekly round-up: Novo Nordisk Foundation announces funding milestone, breakthrough AI results revealed

Our clients finished off January on a positive note, with some great investment news from Commit, a fundraising milestone from the Novo Nordisk Foundation, and breakthrough AI results from BrightHeart. Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year Following its 100th anniversary in 2024, the […]

Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology

Bioptimus announces a $76M funding milestone, with the latest injection of $41M led by Cathay Innovation less than 12 months from its initial seed round Since the successful release of the largest AI foundation model for pathology in July, the company has been continuing its groundbreaking work and is now poised to release a breakthrough […]

Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)

EQT Life Sciences expands the Series B with additional capital, alongside continued support from existing investors, including, Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, and UPMC Enterprises Basel, Switzerland, December 11, 2024 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a […]